Poseltinib is under clinical development by Hanmi Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Poseltinib’s likelihood of approval (LoA) and phase transition for Autoimmune Disorders took place on 13 Jan 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Poseltinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Poseltinib overview

Poseltinib (HM-71224) is under development for the treatment of allergic diseases, autoimmune diseases including systemic lupus erythematosus, diffuse large b-cell lymphoma and follicular lymphoma. The drug candidate is administered through oral route. The drug candidate is a new chemical entity (NCE) targeting Bruton’s tyrosine kinase (BTK). It is based on NCE (new chemical entities) discovery technology. The drug candidate was under development for the treatment of rheumatoid arthritis and other immunological disorders.

Hanmi Pharmaceuticals overview

Hanmi Pharmaceuticals, a subsidiary of Hanmi Science Co Ltd, develops prescription drugs and over the counter (OTC) drugs. The company’s prescription drugs include antibiotics, antidiarrheal, osteoporosis, liver supplements and antiemetics. It provides OTC products such as nutritional supplements, calcium supplement, vitamins, among others. Hanmi Pharmaceuticals products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others. The company operates through its manufacturing facilities located in Hwaseong, Songpa and Pyeongtaek, South Korea. Hanmi Pharmaceuticals is headquartered in Seoul, South Korea.

Quick View Poseltinib LOA Data

Report Segments
  • Innovator
Drug Name
  • Poseltinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Immunology
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.